Hoth Therapeutics (NASDAQ:HOTH – Get Rating) and Oncorus (NASDAQ:ONCR – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability.
Volatility & Risk
Hoth Therapeutics has a beta of 1.11, suggesting that its stock price is 11% more volatile than the S&P 500. Comparatively, Oncorus has a beta of 4.27, suggesting that its stock price is 327% more volatile than the S&P 500.
This table compares Hoth Therapeutics and Oncorus’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional & Insider Ownership
12.4% of Hoth Therapeutics shares are held by institutional investors. Comparatively, 84.3% of Oncorus shares are held by institutional investors. 7.9% of Hoth Therapeutics shares are held by company insiders. Comparatively, 13.7% of Oncorus shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
This is a summary of current ratings and recommmendations for Hoth Therapeutics and Oncorus, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Hoth Therapeutics presently has a consensus target price of $4.00, suggesting a potential upside of 804.98%. Oncorus has a consensus target price of $8.67, suggesting a potential upside of 628.29%. Given Hoth Therapeutics’ higher probable upside, equities analysts clearly believe Hoth Therapeutics is more favorable than Oncorus.
Earnings and Valuation
This table compares Hoth Therapeutics and Oncorus’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Hoth Therapeutics||N/A||N/A||-$14.31 million||($0.56)||-0.79|
Hoth Therapeutics is trading at a lower price-to-earnings ratio than Oncorus, indicating that it is currently the more affordable of the two stocks.
Oncorus beats Hoth Therapeutics on 7 of the 10 factors compared between the two stocks.
About Hoth Therapeutics (Get Rating)
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-003 to treat inflammatory bowel diseases, as well as acne and psoriasis; HT-004 for treatment of asthma and allergies using inhalational administration; HT-006 to treat lung diseases resulting from bacterial infections; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus. The company has license agreements with the George Washington University; the University of Maryland; Isoprene Pharmaceuticals, Inc.; the North Carolina State University; Chelexa BioSciences, Inc.; Zylö Therapeutics, Inc., and the University of Cincinnati. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is headquartered in New York, New York.
About Oncorus (Get Rating)
Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers. It is also developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer through intratumoral injection; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. The company has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 combined with Merck's cancer immunotherapy KEYTRUDA in its Phase 1 clinical trial in patients with solid tumors. Oncorus, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for Hoth Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hoth Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.